Related Experiment Video
Updated: Aug 14, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation
Jae Suk Ahn1, Mala L Radhakrishnan, Marina Mapelli
1Department of Neurology and Laboratory for Drug Discovery in Neurodegeneration, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Abstract:
Cyclin-dependent kinase 5 (Cdk5) is widely viewed as a possible target for a wide variety of neurological disorders. One pathological role attributed to Cdk5 is the abnormal phosphorylation of tau that may lead to the neuronal inclusions known as neurofibrillary tangles. A high through-put screen for inhibitors of Cdk5-mediated phosphorylation of tau resulted in three compounds with distinct mechanisms of action. One compound is competitive with ATP and has a high affinity for the Cdk5 ATP binding pocket. The second compound also competes with ATP, is noncompetitive with tau, and (uniquely among this class of inhibitors) displaces adjacent amino acid residues to make room for the nitrophenyl group. A third compound did not compete with ATP, but did compete with tau at low concentrations of tau. The SAR and charge optimization derived from cocrystals of the two ATP competitors along with cocrystals of three other ATP competitors map out the importance of filling and properly charging different regions of the ATP binding pocket. Taken together, this analysis shows how the structure of Cdk5 constrains the space of potential inhibitors and reveals a pocket unfilled in all of the structures. These leads could be a starting point for structure-based drug design of more potent and selective inhibitors.
Insights
Researchers identified three novel inhibitors targeting Cyclin-dependent kinase 5 (Cdk5), a key factor in neurological disorders. These compounds offer distinct mechanisms for developing new Cdk5-based therapies.
Area of Science:
- Biochemistry
- Neuroscience
- Drug Discovery
Background:
- Cyclin-dependent kinase 5 (Cdk5) is implicated in neurological disorders.
- Abnormal tau phosphorylation by Cdk5 contributes to neurofibrillary tangles.
Purpose of the Study:
- To identify and characterize inhibitors of Cdk5-mediated tau phosphorylation.
- To explore structure-activity relationships for Cdk5 inhibitor design.
Main Methods:
- High-throughput screening for Cdk5 inhibitors.
- Cocrystallography to determine inhibitor-bound Cdk5 structures.
- Structure-activity relationship (SAR) analysis.
Main Results:
- Identified three compounds with distinct inhibitory mechanisms against Cdk5.
- Characterized ATP-competitive and tau-competitive inhibitors.
- Mapped the Cdk5 ATP binding pocket and identified an unfilled region.
Conclusions:
- Cdk5 structure guides the design of potent and selective inhibitors.
- Identified lead compounds for structure-based drug design targeting Cdk5.
- Potential therapeutic strategies for neurological diseases involving Cdk5.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Positive Regulator Molecules
Inhibition of Cdk Activity
Inhibition of CDK Activity